Markets:

Overview

News

Currencies

International

Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

47.99 -0.45 (-0.93%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2

...

30 31 32 33 34 35 36 37 Next >

Bluebird Bio Offers World's Most Expensive Drugs, But Uncertainty Looms Over Its Financial Future ↗

October 03, 2022

Bluebird Bio Inc (NASDAQ: BLUE) is about to become the seller of the two most expensive drugs in the U.S. and probably the world. The price tag of $3 million is already facing backlash.

Via Benzinga

Vertex, Gene-Editing Leader, Heads 5 Resilient Stocks In Bear Market ↗

October 01, 2022

Vertex flashed a buy signal on positive gene-editing news.

Via Investor's Business Daily

Stock Market Falls, S&P 500 Hits Bear Lows; Biogen, Nike, Micron Are Key Movers: Weekly Review ↗

September 30, 2022

The major indexes fell, with the S&P 500 breaking below bear market lows.

Via Investor's Business Daily

MaxCyte Inks Platform License With Vertex For Gene-Editing Program For Rare Blood Disorders ↗

September 28, 2022

MaxCyte Inc (NASDAQ: MXCT) has signed a

Via Benzinga

What Is Going on With Grom Social (GROM) Stock Today? ↗

September 27, 2022

Grom Social (GROM) stock is heading higher on Tuesday following news of Chelsea and Matt Giegerich signing a deal with Curiosity Ink Media.

Via InvestorPlace

Where CRISPR Therapeutics Stands With Analysts ↗

August 02, 2022

CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings within the last quarter:

Via Benzinga

Why Are Crypto Mining Stocks RIOT, MARA, HUT Up Today? ↗

September 27, 2022

Crypto mining stocks are on the move Tuesday as investors react to Bitcoin (BTC) breaking past the $20,000 price point today!

Via InvestorPlace

Why Is Crispr Therapeutics (CRSP) Stock Up Today? ↗

September 27, 2022

Crispr Therapeutics (CRSP) stock is gaining on Tuesday after the FDA granted exagamglogene autotemcel (exa-cel) a rolling review.

Via InvestorPlace

Crispr Stock Jumps After Unveiling Timeline For FDA Submission Of First-Ever CRISPR Drug ↗

September 27, 2022

Crispr and Vertex nailed down the timeline for their blood diseases gene editor.

Via Investor's Business Daily

Why CRISPR Therapeutics Stock Is Rising Today ↗

September 27, 2022

CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading higher Tuesday after the company and Vertex Pharmaceuticals Inc (NASDAQ: VRTX) announced the U.S.

Via Benzinga

S&P 500 Giant Leads 5 Stocks Showing Strength In Bear Market ↗

September 24, 2022

Eli Lilly leads medical stocks setting up and showing relative strength.

Via Investor's Business Daily

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,700 Today ↗

September 20, 2022

CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 20.85% on an annualized basis producing an average annual return of 29.91%. Currently, CRISPR Therapeutics has a...

Via Benzinga

Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing ↗

September 16, 2022

Intellia tested its CRISPR approach in cardiomyopathy and hereditary angioedema.

Via Investor's Business Daily

No One Told These 3 Stocks It’s a Down Week

September 16, 2022

At the individual stock level, there have been some interesting contrarian movers, especially in the electric vehicle (EV) space.

Via MarketBeat

Topics Economy Electric Vehicles

Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin ↗

September 15, 2022

The market is struggling, yet biotech stocks are acting like it's good times again. Here's why.

Via Investor's Business Daily

Neurocrine Leads 5 Stocks To Watch In Sickly Market ↗

September 03, 2022

Neurocrine Biosciences leads five medical stocks showing resilience.

Via Investor's Business Daily

Here's How Much $100 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today ↗

August 31, 2022

CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 16.43% on an annualized basis producing an average annual return of 26.37%. Currently, CRISPR Therapeutics has a...

Via Benzinga

5 Top Stocks Cathie Wood Is Selling This Week ↗

August 26, 2022

Cathie Wood and her flagship ETF ARKK received $54.2 million of inflows earlier this month. Here's what she's selling.

Via InvestorPlace

5 Cathie Wood Stocks Signaling “The Bear Market Is Over” ↗

August 22, 2022

These top Cathie Wood stocks are signalling that the bear market is over. For savvy investors, that presents a chance to profit.

Via InvestorPlace

Why This Analyst Sees A 51% Return On This Cathie Wood-Favored Biotech Stock ↗

August 17, 2022

Biotech stocks have the potential for huge gains if a product or drug is deemed effective and safe, but investing in the shares of those companies can be volatile.

Via Benzinga

$1000 Invested In This Stock 5 Years Ago Would Be Worth $3,900 Today ↗

August 17, 2022

CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 19.58% on an annualized basis producing an average annual return of 31.2%. Currently, CRISPR Therapeutics has a...

Via Benzinga

Analysts See Softened Timelines For CRISPR Therapeutics' Sickle Cell Candidate In US ↗

August 09, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2022 ↗

August 09, 2022

Via Benzinga

Karuna Therapeutics To $276? Plus SVB Leerink Almost Doubles Price Target On This Stock ↗

August 09, 2022

Mizuho boosted the price target for Karuna Therapeutics, Inc. (NASDAQ: KRTX) from $190 to $276. Karuna Therapeutics shares fell 1.3% to $238.00 in pre-market trading.

Via Benzinga

NVIDIA To $240? Here Are 5 Other Price Target Changes For Tuesday ↗

August 09, 2022

Raymond James cut the price target on NVIDIA Corporation (NASDAQ: NVDA) from $250 to $240. Raymond James analyst Melissa Fairbanks maintained the stock with a Strong Buy. NVIDIA shares fell 2.8% to...

Via Benzinga

Small Cap Biotechs Perk Up On Dealmaking ↗

August 06, 2022

With M&A picking up we would think smaller deals make sense for large cap biopharma to expand pipelines and complement technology.

Via Talk Markets

MarketBeat: Week in Review 8/1 - 8/5

August 06, 2022

The hot jobs report is dispelling any notion that interest rates will level off. But the market moves on and here are some of the stocks and stories to follow.

Via MarketBeat

Topics Economy Electric Vehicles

Pfizer Is Reportedly In 'Advanced Talks' To Buy Global Blood Therapeutics For $5 Billion ↗

August 05, 2022

Shares of Pfizer's rumored takeover target have rocketed for two days running.

Via Investor's Business Daily

Cathie Wood Sheds $5M In CRISPR Therapeutics, Scoops Up These Biotech Stocks Instead ↗

August 05, 2022

Cathie Wood-led Ark Investment Management on Thursday sold 70,723 shares of gene editing company CRISPR Therapeutics AG (NASDAQ: CRSP), valued at over $5.58 million, via its flagship fund.

Via Benzinga

Why Are Gene Editing Stocks NTLA, ALNY, CRSP, BEAM Up Today? ↗

August 03, 2022

Gene editing stocks are a bright spot on the market today after Alnylam announced the success of one of its RNAi therapies, Patisiran.

Via InvestorPlace

< Previous 1 2

...

30 31 32 33 34 35 36 37 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.